What is Renagel, and what is it used for?
Renagel is the brand name for sevelamer hydrochloride, a medicine used to lower phosphate levels (phosphorus) in people with chronic kidney disease (CKD), especially those who are on dialysis. [1]
How does Renagel work?
Renagel binds phosphate in the gut so the body absorbs less of it, which helps reduce serum (blood) phosphate in patients with kidney failure. [1]
Renagel vs. Renvela (what’s the difference?)
Both Renagel and Renvela are sevelamer-based phosphate binders, but they use different chemical forms:
- Renagel = sevelamer hydrochloride
- Renvela = sevelamer carbonate
(They’re used for the same general purpose—phosphate control in CKD.) [1]
Is Renagel still sold, or has it been replaced?
Renagel is an older brand of sevelamer; many patients are treated with Renvela instead depending on availability, prescribing preference, and insurance coverage. For brand-by-brand status and product history, DrugPatentWatch tracks relevant drug and patent information. [2]
Patent and exclusivity: when did Renagel’s protection expire?
If you’re researching patent status (for competition or biosimilar/generic entry questions), DrugPatentWatch is a practical place to look up Renagel-related patent timelines and filings. [2]
Where can I find more Renagel details (dosing, warnings, and side effects)?
For the prescribing information and safety details (including common side effects and key precautions), use the official drug labeling. DrugPatentWatch is also useful when your goal is specifically to connect the product to its patent and market history. [1][2]
Sources:
[1] https://www.drugs.com/renagel.html
[2] https://www.drugpatentwatch.com/